scholarly journals Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection.

1996 ◽  
Vol 34 (6) ◽  
pp. 1433-1439 ◽  
Author(s):  
R Nawada ◽  
R Amitani ◽  
E Tanaka ◽  
A Niimi ◽  
K Suzuki ◽  
...  
Keyword(s):  
Murine Model ◽  
Invasive Pulmonary Aspergillosis ◽  
Pulmonary Aspergillosis ◽  
Aspergillus Infection

scholarly journals Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis

2005 ◽  
Vol 49 (7) ◽  
pp. 3028-3030 ◽  
Author(s):  
Joan Gavaldà ◽  
María-Teresa Martín ◽  
Pedro López ◽  
Xavier Gomis ◽  
José-Luís Ramírez ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Murine Model ◽  
Liposomal Amphotericin ◽  
Invasive Pulmonary Aspergillosis ◽  
Liposomal Amphotericin B ◽  
Pulmonary Aspergillosis ◽  
Lower Lung

ABSTRACT The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.

scholarly journals Efficacy of Ambruticin Analogs in a Murine Model of Invasive Pulmonary Aspergillosis

2006 ◽  
Vol 50 (10) ◽  
pp. 3464-3466 ◽  
Author(s):  
Lisa Y. Chiang ◽  
Daniele E. Ejzykowicz ◽  
Zong-Qiang Tian ◽  
Leonard Katz ◽  
Scott G. Filler
Keyword(s):  
Antifungal Activity ◽  
Mouse Model ◽  
Invasive Aspergillosis ◽  
Murine Model ◽  
Antifungal Agents ◽  
Invasive Pulmonary Aspergillosis ◽  
Vehicle Control ◽  
Pulmonary Aspergillosis

ABSTRACT Ambruticins are a family of polyketides. The antifungal activity of an ambruticin, KOSN-2079, was tested in the mouse model of invasive aspergillosis. KOSN-2079 significantly reduced pulmonary fungal burdens and improved survival over that with the vehicle control. These results support the continued development of ambruticins as antifungal agents.

scholarly journals Standardization of an Experimental Murine Model of Invasive Pulmonary Aspergillosis

2006 ◽  
Vol 50 (10) ◽  
pp. 3501-3503 ◽  
Author(s):  
Donald C. Sheppard ◽  
John R. Graybill ◽  
Laura K. Najvar ◽  
Lisa Y. Chiang ◽  
Thomas Doedt ◽  
...  
Keyword(s):  
Murine Model ◽  
Liposomal Amphotericin ◽  
Invasive Pulmonary Aspergillosis ◽  
Therapeutic Agents ◽  
Pulmonary Aspergillosis ◽  
High Level ◽  
Aerosol Infection ◽  
Interlaboratory Reproducibility ◽  
Over Time ◽  
Experimental Murine Model

ABSTRACT Evaluating new therapeutic agents for invasive aspergillosis requires animal models that are reproducible among different laboratories. We therefore evaluated a murine model of aerosol infection in two independent laboratories and found a high level of both intra- and interlaboratory reproducibility of survival, fungal burden over time, and the efficacy of liposomal amphotericin B.

scholarly journals Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

2008 ◽  
Vol 52 (11) ◽  
pp. 4178-4180 ◽  
Author(s):  
Russell E. Lewis ◽  
Nathaniel D. Albert ◽  
Dimitrios P. Kontoyiannis
Keyword(s):  
Body Weight ◽  
Amphotericin B ◽  
Murine Model ◽  
Liposomal Amphotericin ◽  
Invasive Pulmonary Aspergillosis ◽  
Liposomal Amphotericin B ◽  
Potential Utility ◽  
Pulmonary Aspergillosis ◽  
Fungal Burden ◽  
Animal Survival

ABSTRACT In a neutropenic murine model of invasive pulmonary aspergillosis, prophylaxis with single doses of liposomal amphotericin B or micafungin at ≥5 mg/kg of body weight improved animal survival and suppressed the lung fungal burden for up to 7 days after infection, demonstrating the potential utility of infrequent dosing with these antifungals.

scholarly journals Protective Role of Lung Surfactant Protein D in a Murine Model of Invasive Pulmonary Aspergillosis

2001 ◽  
Vol 69 (4) ◽  
pp. 2728-2731 ◽  
Author(s):  
Taruna Madan ◽  
Uday Kishore ◽  
Mamta Singh ◽  
Peter Strong ◽  
Ejaj M. Hussain ◽  
...  
Keyword(s):  
Murine Model ◽  
Lung Surfactant ◽  
Invasive Pulmonary Aspergillosis ◽  
Surfactant Protein ◽  
Protective Role ◽  
Surfactant Protein D ◽  
Protective Effects ◽  
Pulmonary Aspergillosis ◽  
Lung Surfactant Protein

ABSTRACT The protective effects of intranasal administration of amphotericin B (AmB), human SP-A, SP-D and a 60-kDa fragment of SP-D (rSP-D) were examined in a murine model of invasive pulmonary aspergillosis (IPA). The untreated group of IPA mice showed no survival at 7 days postinfection. Treatment with AmB, SP-D, and rSP-D increased the survival rate to 80, 60, and 80%, respectively, suggesting that SP-D (and rSP-D) can protect immunosuppressed mice from an otherwise fatal challenge with Aspergillus fumigatus conidia.

scholarly journals Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19)

2020 ◽  
Vol 59 (1) ◽  
pp. 110-114
Author(s):  
Damien Dupont ◽  
Jean Menotti ◽  
Jean Turc ◽  
Charline Miossec ◽  
Florent Wallet ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Polymerase Chain Reaction ◽  
Invasive Pulmonary Aspergillosis ◽  
Chain Reaction ◽  
Pulmonary Aspergillosis ◽  
Icu Patients ◽  
Aspergillus Infection ◽  
Adult Intensive Care Unit ◽  
Mycological Diagnosis ◽  
Polymerase Chain

Abstract Occurrence of putative invasive pulmonary aspergillosis was screened in 153 consecutive adult intensive care unit (ICU) patients with respiratory samples addressed for mycological diagnosis during a 6-week period at the emergence of coronavirus disease 2019 (COVID-19) pandemic. Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) was observed for 106 patients (69.3%). Nineteen of them (17.9%) with positive Aspergillus results were considered as having putative invasive pulmonary aspergillosis. These observations underline the risk of pulmonary aspergillosis in COVID-19 patients, even in patients not previously known to be immunosuppressed, advocating active search for Aspergillus infection and prompt antifungal treatment. Standardized surveillance protocols and updated definitions for ICU putative invasive pulmonary aspergillosis are needed. Lay Abstract Adult ICU patients with respiratory samples addressed for mycological diagnosis were screened during the emergence of COVID-19 pandemic. Positive SARS-CoV-2 PCR was observed for 106 patients, nineteen of them (17.9%) having aspergillosis. This underlines the risk of aspergillosis in COVID-19 patients.

scholarly journals Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis

2004 ◽  
Vol 48 (5) ◽  
pp. 1908-1911 ◽  
Author(s):  
Donald C. Sheppard ◽  
Gunter Rieg ◽  
Lisa Y. Chiang ◽  
Scott G. Filler ◽  
John E. Edwards ◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Murine Model ◽  
Human Disease ◽  
Invasive Pulmonary Aspergillosis ◽  
Cortisone Acetate ◽  
Pulmonary Aspergillosis ◽  
Aerosol Chamber ◽  
Novel Model

ABSTRACT We developed a novel model of invasive aspergillosis (IA) that recapitulates human disease. Mice were immunosuppressed with cyclophosphamide and cortisone acetate and then infected in an aerosol chamber. This procedure reproducibly delivered 1 × 103 to 3 × 103 conidia to the lungs. Lethal pulmonary IA developed over 2 weeks and was prevented by amphotericin B.

Sign in / Sign up

Export Citation Format

Share Document